Physician profile
Mark A Gentz
NPI 1033153465
$7,441.88
in general payments reported to CMS, 2019-2025
31 companies · $1,070 in 2025
The $1,070 reported for 2025 was more than what 80% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,395 · 2020: $742 · 2021: $1,357 · 2022: $934 · 2023: $510 · 2024: $435 · 2025: $1,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,818 · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,817.55 |
| Education | $196.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,301.91 | 2019-2025 | Cabenuva, Dovato |
| Melinta Therapeutics, LLC | $1,243.97 | 2019-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Janssen Biotech, INC. | $997.92 | 2019-2023 | Symtuza |
| Abbvie INC. | $645.37 | 2021-2025 | |
| Paratek Pharmaceuticals, INC. | $584.19 | 2021-2024 | Nuzyra |
| Janssen Products, LP | $402.51 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $388.22 | 2019-2023 | Pifeltro, Delstrigo, Recarbrio |
| Gilead Sciences, INC. | $386.48 | 2019-2023 | |
| Allergan, INC. | $286.86 | 2019-2020 | |
| Shionogi INC | $238.68 | 2022-2025 | Fetroja |
| Organogenesis INC. | $171.59 | 2023-2025 | Novachor, Affinity, Puraply |
| Exact Sciences Corporation | $102.94 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Theratechnologies INC. | $102.64 | 2020-2021 | |
| Tetraphase Pharmaceuticals, INC. | $101.95 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $72.76 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $62.68 | 2024-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $47.49 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.16 | 2019-2025 | Cuvitru |
| Lifenet Health | $32.50 | 2025 | Theragenesis Wound Matrix |
| Inspire Medical Systems, INC. | $31.53 | 2024 | Inspire |
| Amgen INC. | $29.62 | 2019 | |
| Next Science LLC | $25.95 | 2023 | Surgx, Xperience, Blastx |
| Sunovion Pharmaceuticals INC. | $22.62 | 2019 | |
| Ferring Pharmaceuticals INC. | $19.83 | 2024 | Rebyota |
| Abbott Laboratories | $18.02 | 2024 | Freestyle Libre 3 |
| Napo Pharmaceuticals INC | $15.92 | 2023 | Mytesi |
| Nabriva Therapeutics, Plc | $15.87 | 2022 | |
| Sanofi Pasteur INC. | $15.83 | 2019 | |
| Vyera Pharmaceuticals, LLC | $13.28 | 2019 | |
| Insmed, INC. | $11.64 | 2022 | |
| Lilly USA, LLC | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gentz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.